Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.77 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.77 |
| ▸ | RAF1 | P04049 | 2/20 | 0.77 |
| ▸ | KDR | P35968 | 2/20 | 0.77 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.77 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.77 |
| ▸ | NEK2 | P51955 | 2/20 | 0.77 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.77 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.77 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.77 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.77 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 0.77 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.77 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | EGFR | P00533 | 1/20 | 0.77 |
| ▸ | KRAS | P01116 | 1/20 | 0.77 |
| ▸ | PGR | P06401 | 1/20 | 0.77 |
| ▸ | RET | P07949 | 1/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20399247 | 0.94 | BRAF (0.77) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL15677279 | 0.93 | CYP2C19 (0.65) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL20399491 | 0.92 | BRAF (0.76) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298795 | 0.91 | BRAF (0.75) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL7876722 | 0.89 | BRAF (0.89) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL299358 | 0.89 | CYP2C9 (0.72) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL20399951 | 0.89 | BRAF (0.77) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL20399246 | 0.89 | BRAF (0.79) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL18759307 | 0.88 | BRAF (0.83) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298547 | 0.88 | BRAF (0.80) | BRAFRIPK2RAF1KDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-2672967-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20170157120-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157120-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157120-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9624213-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624213-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-18 | — | — | US | disclosed |
| EP-3004060-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2016-04-13 | — | — | EP | disclosed |
| CN-105228983-A | The compound regulated for kinases and indication thereof | PLEXXIKON INC | 2016-01-06 | — | — | CN | disclosed |
| WO-2014194127-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
| EP-2672967-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012109075-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K20, PRKACA, MAP3K13 | BRAF 49/4885RIPK2 504/4885RAF1 74/4885 |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | BRAF 49/4885RIPK2 504/4885RAF1 74/4885 |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | BRAF 49/4885RIPK2 504/4885RAF1 74/4885 |
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | BRAF 49/4885RIPK2 504/4885RAF1 74/4885 |
| US-20170157120-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | BRAF 49/4885RIPK2 504/4885RAF1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.